NCT04322292 2026-02-11
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Completed
Clinical Trials
327 trialsNCT04674813 2026-02-09
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, a Subsidiary of Celgene
Phase 1 Completed
NCT03275103 2026-02-05
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Genentech, Inc.
Phase 1 Completed
NCT02407509 2026-01-29
RAF/MEK
Royal Marsden NHS Foundation Trust
Phase 1 Completed
NCT03702725 2026-01-06
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Alliance Foundation Trials, LLC.
Phase 1 Completed
NCT05182073 2025-12-12
FT576 in Subjects With Multiple Myeloma
Fate Therapeutics
Phase 1 Completed
NCT02199665 2025-11-03
SINE
University of Chicago
Phase 1 Completed
NCT03602235 2025-10-21
High Dose Ascorbic Acid for Plasma Cell Disorders
University of Iowa
Phase 1 Completed
NCT04773522 2025-10-01
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Janssen Pharmaceutical K.K.
Phase 1 Completed
NCT04000282 2025-09-12
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma
Sanofi
Phase 1 Completed
NCT04045795 2025-09-12
Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Sanofi
Phase 1 Completed
NCT06547112 2025-08-29
A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization
Washington University School of Medicine
Phase 1 Completed
NCT04772989 2025-08-28
ARC-12
Arcus Biosciences, Inc.
Phase 1 Completed
NCT03828292 2025-08-19
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
GlaxoSmithKline
Phase 1 Completed
NCT01711671 2025-08-03
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Leap Therapeutics, Inc.
Phase 1 Completed
NCT04813653 2025-07-24
Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells
Tel-Aviv Sourasky Medical Center
Phase 1 Completed
NCT05011097 2025-07-20
A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma
Wuhan YZY Biopharma Co., Ltd.
Phase 1 Completed
NCT02546167 2025-06-25
CART-BCMA Cells for Multiple Myeloma
University of Pennsylvania
Phase 1 Completed
NCT03770260 2025-06-19
Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment
National Cancer Institute (NCI)
Phase 1 Completed
NCT05567601 2025-06-05
Doxil/Caelyx BE Study
Baxter Healthcare Corporation
Phase 1 Completed
NCT02519452 2025-05-23
A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT01998971 2025-04-25
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT00511082 2025-04-16
Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Otsuka Beijing Research Institute
Phase 1 Completed
NCT04758767 2025-04-03
CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma
CASI Pharmaceuticals, Inc.
Phase 1 Completed
NCT01163357 2025-03-26
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
City of Hope Medical Center
Phase 1 Completed
NCT01758328 2025-03-20
Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT04177823 2025-03-20
A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline
Phase 1 Completed
NCT05227144 2025-03-20
Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
ORIC Pharmaceuticals
Phase 1 Completed
NCT05243342 2025-02-17
A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma
Genentech, Inc.
Phase 1 Completed
NCT03762291 2025-02-05
MAPSS
Baylor College of Medicine
Phase 1 Completed
NCT02918331 2025-02-03
A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation
Janssen Pharmaceutical K.K.
Phase 1 Completed
NCT05896774 2024-11-20
A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China
Pfizer
Phase 1 Completed
NCT02043847 2024-11-13
BMT-03
University of Illinois at Chicago
Phase 1 Completed
NCT03524235 2024-11-12
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Cedars-Sinai Medical Center
Phase 1 Completed
NCT05567887 2024-11-06
A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies
Pfizer
Phase 1 Completed
NCT03399539 2024-11-04
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma
Mayo Clinic
Phase 1 Completed
NCT04398485 2024-10-31
A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma
Ionis Pharmaceuticals, Inc.
Phase 1 Completed
NCT04798586 2024-09-27
MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma
Pfizer
Phase 1 Completed
NCT02616640 2024-09-19
A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Celgene
Phase 1 Completed
NCT03829020 2024-08-22
Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
Mayo Clinic
Phase 1 Completed
NCT02148913 2024-07-26
Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
Corewell Health West
Phase 1 Completed
NCT04394650 2024-07-26
A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, a Subsidiary of Celgene
Phase 1 Completed
NCT02576496 2024-07-25
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Mundipharma Research Limited
Phase 1 Completed
NCT02920697 2024-07-25
Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma
Servier
Phase 1 Completed
NCT04434469 2024-07-03
A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma
Genentech, Inc.
Phase 1 Completed
NCT05679258 2024-06-28
A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects
Shanghai Henlius Biotech
Phase 1 Completed
NCT03309111 2024-06-13
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
Ichnos Sciences SA
Phase 1 Completed
NCT03424603 2024-06-11
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Sutro Biopharma, Inc.
Phase 1 Completed
NCT02184533 2024-05-28
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer
Stanford University
Phase 1 Completed
NCT03143985 2024-05-24
Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma
Case Comprehensive Cancer Center
Phase 1 Completed